$GHSI
Guardion Health Sciences Inc

2022 Q3 Form 10-Q Financial Statement

#000149315222021971 Filed on August 11, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $2.664M $3.275M $2.385M
YoY Change -15.41% 167.64% 936.79%
Cost Of Revenue $1.575M $1.876M $1.288M
YoY Change -10.52% 181.96% 890.89%
Gross Profit $1.088M $1.400M $1.096M
YoY Change -21.6% 150.59% 996.46%
Gross Profit Margin 40.85% 42.73% 45.98%
Selling, General & Admin $2.758M $3.016M $3.686M
YoY Change -32.32% 1.24% 34.02%
% of Gross Profit 253.46% 215.47% 336.13%
Research & Development $60.20K $95.52K $6.690K
YoY Change 270.94% 470.09% -66.55%
% of Gross Profit 5.53% 6.83% 0.61%
Depreciation & Amortization $14.72K $19.63K $317.1K
YoY Change -95.36% -0.35% 1485.25%
% of Gross Profit 1.35% 1.4% 28.92%
Operating Expenses $2.828M $3.111M $3.692M
YoY Change -30.89% -38.99% 33.29%
Operating Profit -$1.739M -$1.712M -$2.596M
YoY Change -35.66% -62.3% -2.78%
Interest Expense $43.28K $9.620K $1.560K
YoY Change
% of Operating Profit
Other Income/Expense, Net $916.5K $9.615K -$2.681M
YoY Change 3514.66%
Pretax Income -$1.696M -$1.702M -$2.618M
YoY Change -43.74% -62.51% -1.93%
Income Tax
% Of Pretax Income
Net Earnings -$1.696M -$1.702M -$2.618M
YoY Change -43.74% -62.51% -1.91%
Net Earnings / Revenue -63.68% -51.96% -109.81%
Basic Earnings Per Share -$0.03 -$0.03 -$7.00
Diluted Earnings Per Share -$27.53K -$27.65K -$66.88K
COMMON SHARES
Basic Shares Outstanding 61.60M shares 61.55M shares 783.0K shares
Diluted Shares Outstanding 1.232M shares 1.231M shares

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $12.95M $14.23M $16.83M
YoY Change 22.61% 13.83% -61.16%
Cash & Equivalents $12.95M $4.225M $4.832M
Short-Term Investments $0.00 $10.01M $12.00M
Other Short-Term Assets $1.038M $1.156M $717.6K
YoY Change -16.71% -3.92% 131.49%
Inventory $1.953M $1.710M $822.3K
Prepaid Expenses $1.038M $1.156M
Receivables $1.874M $2.002M $2.198M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $17.81M $19.10M $20.57M
YoY Change 19.81% 15.43% -53.25%
LONG-TERM ASSETS
Property, Plant & Equipment $53.76K $74.60K $94.23K
YoY Change -82.01% -87.25% -85.5%
Goodwill
YoY Change
Intangibles $10.36M $10.66M
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $10.42M $10.74M $11.05M
YoY Change -56.13% -56.6% 1478.94%
TOTAL ASSETS
Total Short-Term Assets $17.81M $19.10M $20.57M
Total Long-Term Assets $10.42M $10.74M $11.05M
Total Assets $28.23M $29.83M $31.62M
YoY Change -26.89% -27.73% -29.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.041M $1.096M $1.146M
YoY Change -12.03% 42.62% 398.42%
Accrued Expenses $683.2K $582.3K $680.0K
YoY Change -13.21% -43.83% 0.01%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.733M $1.693M $1.826M
YoY Change -12.02% -6.19% 86.37%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.733M $1.693M $1.826M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.733M $1.693M $1.826M
YoY Change -12.02% -14.97% 50.94%
SHAREHOLDERS EQUITY
Retained Earnings -$84.82M -$83.12M -$84.10M
YoY Change
Common Stock $61.60K $61.60K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $26.49M $28.14M $29.79M
YoY Change
Total Liabilities & Shareholders Equity $28.23M $29.83M $31.62M
YoY Change -26.89% -27.73% -29.26%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$1.696M -$1.702M -$2.618M
YoY Change -43.74% -62.51% -1.91%
Depreciation, Depletion And Amortization $14.72K $19.63K $317.1K
YoY Change -95.36% -0.35% 1485.25%
Cash From Operating Activities -$1.282M -$2.574M -$2.226M
YoY Change -28.48% -47.09% -8.0%
INVESTING ACTIVITIES
Capital Expenditures -$3.170K $0.00 -$2.400K
YoY Change -95.81% -100.0%
Acquisitions
YoY Change
Other Investing Activities $10.01M $1.990M -$7.002M
YoY Change -14381.09% -106.04%
Cash From Investing Activities $10.00M $1.990M -$7.004M
YoY Change -6964.0% -106.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 -24.01K 9.969M
YoY Change -2477.23% -73.22%
NET CHANGE
Cash From Operating Activities -1.282M -2.574M -2.226M
Cash From Investing Activities 10.00M 1.990M -7.004M
Cash From Financing Activities 0.000 -24.01K 9.969M
Net Change In Cash 8.721M -607.9K 738.6K
YoY Change -549.89% -98.39%
FREE CASH FLOW
Cash From Operating Activities -$1.282M -$2.574M -$2.226M
Capital Expenditures -$3.170K $0.00 -$2.400K
Free Cash Flow -$1.279M -$2.574M -$2.224M
YoY Change -25.52% -47.08% -8.1%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
20844 usd
GHSI Noncash Adjust Warrant Liability
NoncashAdjustWarrantLiability
25978 usd
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-4428421
dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
dei Entity Central Index Key
EntityCentralIndexKey
0001642375
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
usd
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
usd
us-gaap Increase Decrease In Due To Officers And Stockholders
IncreaseDecreaseInDueToOfficersAndStockholders
usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
dei Entity Address Address Line1
EntityAddressAddressLine1
2925 Richmond Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1200
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
GHSI Noncash Adjust Warrant Liability
NoncashAdjustWarrantLiability
usd
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
61600803 shares
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
usd
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
usd
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
shares
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4224551 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4093927 usd
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38861
dei Entity Registrant Name
EntityRegistrantName
GUARDION HEALTH SCIENCES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77098
dei City Area Code
CityAreaCode
800
dei Local Phone Number
LocalPhoneNumber
873-5141
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
GHSI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 us-gaap Short Term Investments
ShortTermInvestments
10006758 usd
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
4995623 usd
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2002466 usd
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1411567 usd
CY2022Q2 us-gaap Inventory Net
InventoryNet
1709557 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
367691 usd
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1155976 usd
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1200376 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
19099308 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
12069184 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
74602 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
111378 usd
CY2022Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
10660833 usd
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
11255833 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
24257 usd
CY2022Q2 us-gaap Assets
Assets
29834743 usd
CY2021Q4 us-gaap Assets
Assets
23460652 usd
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1095800 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
241347 usd
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
582311 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
895477 usd
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
15083 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
22221 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1693194 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1159045 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3807 usd
CY2022Q2 us-gaap Liabilities
Liabilities
1693194 usd
CY2021Q4 us-gaap Liabilities
Liabilities
1162852 usd
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
24257 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
3111122 usd
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
61600803 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
61600803 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24426993 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24426993 shares
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
61601 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
24427 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
111202470 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
101075445 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-83122522 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-78802072 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
28141549 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
22297800 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
29834743 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
23460652 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3275213 usd
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1223720 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5659832 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1457017 usd
CY2022Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1875669 usd
CY2021Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
665219 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3163831 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
798255 usd
CY2022Q2 us-gaap Gross Profit
GrossProfit
1399544 usd
CY2021Q2 us-gaap Gross Profit
GrossProfit
558501 usd
us-gaap Gross Profit
GrossProfit
2496001 usd
us-gaap Gross Profit
GrossProfit
658762 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
95524 usd
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16756 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
102215 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
37364 usd
CY2022Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
388511 usd
CY2021Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
440793 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1057156 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
898520 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2627087 usd
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2537826 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5643999 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4829277 usd
CY2021Q2 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
2103680 usd
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
2103680 usd
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
5099055 usd
us-gaap Operating Expenses
OperatingExpenses
6827627 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-4540288 usd
us-gaap Net Income Loss
NetIncomeLoss
-4320450 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
43490633 usd
us-gaap Operating Expenses
OperatingExpenses
7868841 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1711578 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4540554 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-4331626 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-7210079 usd
CY2022Q2 us-gaap Interest Income Other
InterestIncomeOther
9615 usd
CY2021Q2 us-gaap Interest Income Other
InterestIncomeOther
266 usd
us-gaap Interest Income Other
InterestIncomeOther
11176 usd
us-gaap Interest Income Other
InterestIncomeOther
266 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
9615 usd
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
266 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
11176 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
266 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-1701963 usd
us-gaap Net Income Loss
NetIncomeLoss
-7209813 usd
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61553137 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24426993 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50462141 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22897683 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
22297800 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
85963 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
59906 usd
CY2022Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
8834899 usd
CY2022Q1 GHSI Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
1134040 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2618487 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
29794120 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
61818 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
11585 usd
CY2022Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-24011 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-1701963 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
28141549 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
8515266 usd
CY2021Q1 GHSI Cumulative Effect Adjustment
CumulativeEffectAdjustment
26265 usd
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
205772 usd
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
181843 usd
CY2021Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
33662597 usd
CY2021Q1 GHSI Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
3568415 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-2669525 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
43490633 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
183452 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
159640 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4093927 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8518732 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-4540288 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
39293437 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
39293437 usd
us-gaap Net Income Loss
NetIncomeLoss
-4320450 usd
us-gaap Net Income Loss
NetIncomeLoss
-7209813 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
634180 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
140275 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
78328 usd
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
24257 usd
GHSI Fair Value Of Vested Stock Options
FairValueOfVestedStockOptions
147781 usd
GHSI Fair Value Of Vested Stock Options
FairValueOfVestedStockOptions
389224 usd
GHSI Fair Value Of Vested Restricted Common Stock
FairValueOfVestedRestrictedCommonStock
71491 usd
GHSI Fair Value Of Vested Restricted Common Stock
FairValueOfVestedRestrictedCommonStock
341483 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
170403 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
218538 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1341866 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-41776 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
376098 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1276545 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
854453 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-32462 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-10945 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-79621 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-313165 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
689497 usd
us-gaap Increase Decrease In Due To Officers And Stockholders
IncreaseDecreaseInDueToOfficersAndStockholders
-148958 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4800765 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7285354 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2404 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1142 usd
GHSI Payments To Acquire Treasury Bills
PaymentsToAcquireTreasuryBills
61956783 usd
GHSI Payments To Acquire Treasury Bills
PaymentsToAcquireTreasuryBills
35000000 usd
GHSI Proceeds From Sale Of Treasury Bills
ProceedsFromSaleOfTreasuryBills
56945648 usd
GHSI Proceeds From Sale Of Treasury Bills
ProceedsFromSaleOfTreasuryBills
27999734 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
25960572 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5013539 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-32961980 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8834899 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
33662599 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1134040 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3568415 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
24011 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9944928 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
37231013 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
130624 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3016321 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4224551 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5502411 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
11950000 usd
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
11950000 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1289167 usd
us-gaap Net Income Loss
NetIncomeLoss
-4320450 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4800765 usd
CY2022Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
14231309 usd
CY2022Q2 GHSI Working Capital
WorkingCapital
17406114 usd
CY2022Q1 GHSI Minimum Closing Bid Price Value
MinimumClosingBidPriceValue
1.00
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-30 split
us-gaap Number Of Reporting Units
NumberOfReportingUnits
1 segment
CY2021 us-gaap Number Of Reporting Units
NumberOfReportingUnits
1 segment
CY2021Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
one-for-six (1:6) reverse stock split
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
694167 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84B_eus-gaap--UseOfEstimates_zOVnRv5fPXzl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zipAKrm2NLNb">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of our financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities. On an ongoing basis, management reviews its estimates and, if deemed appropriate, those estimates are adjusted. Significant estimates include those related to assumptions used in valuing inventories at net realizable value, assumptions used in valuing assets acquired in business acquisitions, impairment testing of goodwill and other long-term assets, assumptions used in valuing stock-based compensation, the valuation allowance for deferred tax assets, accruals for potential liabilities, and assumptions used in the determination of the Company’s liquidity. Actual results could differ materially from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3275213 usd
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1223720 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5659832 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1457017 usd
CY2022Q2 GHSI Third Party Outsourcing
ThirdPartyOutsourcing
1847000 usd
GHSI Third Party Outsourcing
ThirdPartyOutsourcing
3075000 usd
CY2021Q2 GHSI Third Party Outsourcing
ThirdPartyOutsourcing
719000 usd
GHSI Third Party Outsourcing
ThirdPartyOutsourcing
719000 usd
CY2022Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
10660833 usd
CY2022Q2 us-gaap Advertising Expense
AdvertisingExpense
292368 usd
CY2021Q2 us-gaap Advertising Expense
AdvertisingExpense
253428 usd
us-gaap Advertising Expense
AdvertisingExpense
879730 usd
us-gaap Advertising Expense
AdvertisingExpense
611491 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_84D_eus-gaap--ConcentrationRiskCreditRisk_zIddDQin0yT4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zlqP9U6WXuHg">Concentrations</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenue. </i>During the three months ended June 30, 2022, the Company had one customer that accounted for <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zLNFs33BJ8Ej">56</span>% of total revenue. During the three months ended June 30, 2021, the Company had two customers that accounted for <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zAyQRVk1Hpfd">39</span>% and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zC8FjM7jRYh">13</span>% of the Company’s total revenue. No other customer accounted for more than <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherCustomersMember__srt--RangeAxis__srt--MinimumMember_zgpOOlTld95k"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherCustomersMember__srt--RangeAxis__srt--MinimumMember_z2yKXm4CrQFh">10</span></span>% of revenue<span style="background-color: white">, </span>during the three months ended June 30, 2022 and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the six months ended June 30, 2022, the Company had one customer that accounted for <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zd9nQNjaBqNi" title="Concentration Risk, Percentage">57</span>% of total revenue. During the six months ended June 30, 2021, the Company had two customers that accounted for <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zsGgVnjEmLWj" title="Concentration Risk, Percentage">33</span>% and <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zgX5t3Upqkga">11</span>% of the Company’s total revenue. No other customer accounted for more than <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherCustomersMember__srt--RangeAxis__srt--MinimumMember_z8fx66lgrDbb" title="Concentration Risk, Percentage"><span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherCustomersMember__srt--RangeAxis__srt--MinimumMember_zmVMALEjl6Nf">10</span></span>% of revenue<span style="background-color: white">, </span>during the six months ended June 30, 2022 and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Accounts receivable</i>. As of </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 30, 2022<span style="background-color: white">, the Company had accounts receivable from one customer which comprised approximately <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zm5LaDgQt3X3" title="Concentration Risk, Percentage">61</span>% of its accounts receivable. As of </span>December 31, 2021<span style="background-color: white">, the Company had accounts receivable from two customers which comprised approximately <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zCvBbqhVUuSb" title="Concentration Risk, Percentage">50</span>% and <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zQvUg1GXLbP4" title="Concentration Risk, Percentage">48</span>% of its accounts receivable. No other customer accounted for more than <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherCustomersMember__srt--RangeAxis__srt--MinimumMember_zZGsckRXx6dd" title="Concentration Risk, Percentage"><span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherCustomersMember__srt--RangeAxis__srt--MinimumMember_zqohbDtMdCc8" title="Concentration Risk, Percentage">10</span></span>% of accounts receivable as of </span>June 30, 2022 <span style="background-color: white">and December 31, 2021. Historically we have not experienced any collectability issues with this customer.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Purchases from vendors</i>. During the </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">three months and six months ended June 30, 2022<span style="background-color: white">, the Company utilized one manufacturer for most of its production and packaging of its clinical nutrition products. Total purchases from this manufacturer accounted for approximately <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneManufacturerMember_zy33cqHcXhF6" title="Concentration Risk, Percentage">43</span>% of all purchases during the three months ended June 30, 2022. There was one other vendor during the three months ended </span>June 30<span style="background-color: white">, 2022 that accounted for <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherVendorMember_zCkhyCX502Bb">13</span>% of total purchases. During the </span>three months ended June 30, 2021<span style="background-color: white">, the Company’s largest vendor accounted for approximately <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorMember_zkmwMmDm0hi" title="Concentration Risk, Percentage">38</span>% of all purchases. During the six months ended June 30, 2021, the Company’s largest vendors accounted for approximately <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorOneMember_zsUVzLlm98Dl" title="Concentration Risk, Percentage">16</span>% and <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorTwoMember_zzYMAlcixdH1">15</span>% of all purchases. No other vendor accounted for more than <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherVendorMember__srt--RangeAxis__srt--MinimumMember_zHRB5WzCqrR7" title="Concentration Risk, Percentage"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherVendorMember__srt--RangeAxis__srt--MinimumMember_zVcMoi4JNA1l" title="Concentration Risk, Percentage"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherVendorMember__srt--RangeAxis__srt--MinimumMember_zF56baOazsu6"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherVendorMember__srt--RangeAxis__srt--MinimumMember_z8vO013xnjRg">10</span></span></span></span>% of purchases during the </span>three months and six months ended June 30, 2022 <span style="background-color: white">and 2021.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Accounts payable</i>. As of </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 30, 2022<span style="background-color: white">, one vendor accounted for <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneVendorMember_zulUlpp7VPg3" title="Concentration Risk, Percentage">87</span>% of total accounts payable. As of </span>December 31, 2021, <span style="background-color: white">the Company’s largest two vendors accounted for <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorOneMember_zifHbrEQ6NT4" title="Concentration Risk, Percentage">18</span>% and <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorTwoMember_zUZr3Ff0vI53" title="Concentration Risk, Percentage">13</span>% of the total accounts payable. No other vendor accounted for more than <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherVendorMember__srt--RangeAxis__srt--MinimumMember_zQeWxTkRFUJi" title="Concentration Risk, Percentage"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherVendorMember__srt--RangeAxis__srt--MinimumMember_zp5viAqWXjTj" title="Concentration risk, percentage">10</span></span>% of accounts payable as of </span>June 30, 2022 <span style="background-color: white">and December 31, 2021.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2021Q2 GHSI Business Acquisition Pro Forma Earnings Per Share Basic And Diluted
BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted
-0.10
GHSI Business Acquisition Pro Forma Earnings Per Share Basic And Diluted
BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted
-0.20
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
11255833 usd
CY2021Q2 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P10Y
us-gaap Payments For Rent
PaymentsForRent
16107 usd
us-gaap Payments For Rent
PaymentsForRent
98486 usd
us-gaap Indefinitelived Intangible Assets Acquired
IndefinitelivedIntangibleAssetsAcquired
50000 usd
CY2021 us-gaap Indefinitelived Intangible Assets Acquired
IndefinitelivedIntangibleAssetsAcquired
50000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
75350138 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1463154 shares
CY2022Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
10006758 usd
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
4995623 usd
CY2020Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
26265 usd
CY2021Q2 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
3016094 usd
us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
6989810 usd
CY2021Q2 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-2434005 usd
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-4641387 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
24257 usd
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
24257 usd
CY2022Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
118139 usd
CY2021Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
53320 usd
CY2022Q2 us-gaap Inventory Finished Goods And Work In Process Net Of Reserves
InventoryFinishedGoodsAndWorkInProcessNetOfReserves
1591418 usd
CY2021Q4 us-gaap Inventory Finished Goods And Work In Process Net Of Reserves
InventoryFinishedGoodsAndWorkInProcessNetOfReserves
314371 usd
CY2022Q2 us-gaap Inventory Net
InventoryNet
1709557 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
367691 usd
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
224048 usd
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
247705 usd
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
149446 usd
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
136327 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
74602 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
111378 usd
CY2022Q2 us-gaap Depreciation
Depreciation
19630 usd
CY2021Q2 us-gaap Depreciation
Depreciation
19698 usd
us-gaap Depreciation
Depreciation
39180 usd
us-gaap Depreciation
Depreciation
41107 usd
us-gaap Cost Of Goods And Services Sold Depreciation
CostOfGoodsAndServicesSoldDepreciation
26060 usd
GHSI Removal Of Depreciation
RemovalOfDepreciation
26060 usd
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
26028 usd
CY2022Q2 us-gaap Finite Lived Trade Names Gross
FiniteLivedTradeNamesGross
9200000 usd
CY2021Q4 us-gaap Finite Lived Trade Names Gross
FiniteLivedTradeNamesGross
9200000 usd
CY2022Q2 us-gaap Finite Lived Customer Relationships Gross
FiniteLivedCustomerRelationshipsGross
2700000 usd
CY2021Q4 us-gaap Finite Lived Customer Relationships Gross
FiniteLivedCustomerRelationshipsGross
2700000 usd
CY2022Q2 us-gaap Finite Lived Trademarks Gross
FiniteLivedTrademarksGross
50000 usd
CY2021Q4 us-gaap Finite Lived Trademarks Gross
FiniteLivedTrademarksGross
50000 usd
CY2022Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
297500 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
595000 usd
CY2021Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
99167 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
99167 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
595000 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1190000 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1190000 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1190000 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1190000 usd
CY2022Q2 GHSI Finite Lived Intangible Assets Amortization Expense After Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
5255833 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
10610833 usd
CY2022Q2 us-gaap Payments For Rent
PaymentsForRent
4473 usd
CY2021Q2 us-gaap Payments For Rent
PaymentsForRent
52585 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
10945 usd
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
15083 usd
CY2022Q2 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.039 pure
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
11478 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3826 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
15304 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
221 usd
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
15083 usd
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
15083 usd
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
74485067 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
853088 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.34
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y6M
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
66668 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.15
GHSI Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term Granted
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted
P5Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
88018 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
831738 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.19
GHSI Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm
P6Y
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
600117 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
831738 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
600117 shares

Files In Submission

Name View Source Status
0001493152-22-021971-index-headers.html Edgar Link pending
0001493152-22-021971-index.html Edgar Link pending
0001493152-22-021971.txt Edgar Link pending
0001493152-22-021971-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
ghsi-20220630.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
ghsi-20220630_cal.xml Edgar Link unprocessable
ghsi-20220630_lab.xml Edgar Link unprocessable
ghsi-20220630_pre.xml Edgar Link unprocessable
ghsi-20220630_def.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable